Table 1 Baseline demographic and clinical characteristics of patients starting a new PI-based cART regimen
| Â | Â | Starting therapy with | ATV/r | FPV/r | SQV/r | pa |
|---|---|---|---|---|---|---|
Characteristic | Â | Â | Â | Â | Â | Â |
Number of patients | Â | N | 84 | 23 | 17 | Â |
DEMOGRAPHIC CHARACTERISTICS | Â | Â | Â | Â | Â | Â |
Male patients | Â | n (%) | 62 (74) | 18 (78) | 14 (82) | 0.72 |
Age (years) | Â | Median | 43 | 44 | 41 | 0.69 |
| Â | Â | (IQRb) | (37; 54) | (38; 50) | (35; 50) | Â |
Caucasian patients | Â | n (%) | 66 (79) | 21 (91) | 14 (82) | 0.71 |
HIV risk category | MSM c | n (%) | 41 (49) | 14 (61) | 12 (70) | Â |
| Â | heterosexual | n (%) | 17 (20) | 4 (17) | 2 (12) | 0.76 |
| Â | Other | n (%) | 26 (31) | 5 (22) | 3 (18) | Â |
HIV DISEASE CHARACTERISTICS | Â | Â | Â | Â | Â | Â |
Duration of known HIV infection (years) | Â | Median | 8.8 | 10.5 | 8.8 | 0.41 |
| Â | Â | (IQR) | (5.4; 12.8) | (6.3; 15.3) | (4.7; 10.5) | Â |
Previous AIDS | Â | n (%) | 34 (40) | 8 (35) | 9 (53) | 0.53 |
CD4 cell count (cells/μl blood) |  | Median | 343 | 320 | 262 | 0.59 |
| Â | Â | (IQR) | (221; 496) | (138; 595) | (81; 551) | Â |
Patients with undetectable viral load d | Â | n (%) | 37 (44) | 8 (35) | 6 (35) | 0.73 |
ANTIRETROVIRAL THERAPY | Â | Â | Â | Â | Â | Â |
Previous cART exposure | Â | n (%) | 79 (94) | 20 (87) | 16 (94) | 0.50 |
Previous PI exposure | Â | n (%) | 55 (66) | 15 (65) | 14 (82) | 0.40 |
Cumulative cART exposure (years) | Â | Median | 6,9 | 7,3 | 5,2 | 0.30 |
| Â | Â | (IQR) | (3.2; 8.7) | (3.8; 9.6) | (3.5; 8.7) | Â |
previous cART | no cART | n (%) | 15 (18) | 8 (35) | 1 (6) | 0.35 |
| Â | other PI | n (%) | 40 (48) | 11 (48) | 10 (59) | 0.69 |
| Â | NRTI and/or NNRTI only | n (%) | 29 (35) | 4 (17) | 6 (35) | 0.12 |
CARDIOVASCULAR RISK FACTORS | Â | Â | Â | Â | Â | Â |
BMI | Â | Median | 23,7 | 23,6 | 21,5 | 0.50 |
| Â | Â | (IQR) | (21.3; 25.4) | (20.5; 25.1) | (19.3; 23.2) | Â |
Current smoker | Â | n (%) | 39 (46) | 9 (39) | 6 (35) | 0.23 |
Arterial hypertension e | Â | n (%) | 35 (42) | 11 (48) | 6 (35) | 0.73 |
Diabetes mellitus | Â | n (%) | 7 (8) | 1 (4) | 0 (0) | 0.40 |
Current lipid-lowering therapy | Â | n (%) | 5 (6) | 2 (9) | 2 (12) | 0.67 |